Fulcrum Therapeutics Inc (FULC) Stock Price, Quote & News

Latest News on FULC

Apr 11, 2025, 4:30 PM EDT - 12 days ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2025, 4:05 PM EST - 7 weeks ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Feb 25, 2025, 10:58 PM EST - 2 months ago

Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:00 AM EST - 2 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 2 months ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Feb 6, 2025, 4:05 PM EST - 2 months ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 26, 2024, 4:05 PM EST - 5 months ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Nov 13, 2024, 7:48 PM EST - 5 months ago

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 5 months ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 8:00 AM EST - 6 months ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Oct 7, 2024, 2:03 PM EDT - 7 months ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Oct 2, 2024, 6:30 PM EDT - 7 months ago

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Oct 1, 2024, 6:15 PM EDT - 7 months ago

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Sep 30, 2024, 8:00 PM EDT - 7 months ago

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Sep 28, 2024, 8:00 PM EDT - 7 months ago

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Sep 27, 2024, 6:30 PM EDT - 7 months ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

Sep 27, 2024, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out

Sep 26, 2024, 6:40 PM EDT - 7 months ago

Fulcrum Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Investors To Lend A Hand

Sep 26, 2024, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation

Sep 25, 2024, 10:00 AM EDT - 7 months ago

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Sep 24, 2024, 6:00 PM EDT - 7 months ago

Fulcrum Therapeutics Inc May Have Defrauded The Public And Affected Investors Should Join The Schall Law Firm's Inquiry

Sep 24, 2024, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation

Sep 23, 2024, 10:00 AM EDT - 7 months ago

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation!

Sep 22, 2024, 7:00 PM EDT - 7 months ago

Fulcrum Therapeutics Inc May Have Engaged In Securities Fraud And The Schall Law Firm Encourages Affected Investors To Join An Inquiry

Sep 22, 2024, 10:00 AM EDT - 7 months ago

Market Cap	197.02M
Revenue (ttm)	80.00M
Net Income (ttm)	-9.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-12.16%
Debt to Equity Ratio	0.00

Volume	712,700
Avg Vol	411,134
Day's Range	N/A - N/A
Shares Out	53.98M
Stochastic %K	80%
Beta	2.13
Analysts	Sell
Price Target	$5.67